Citations

Showing 10 of 108152 citations.

ST8Sia6 Promotes Tumor Growth in Mice by Inhibiting Immune Responses
Friedman, David J. , Crotts, Sydney B. , Shapiro, Michael J. , Rajcula, Matthew, McCue, Shaylene , Khazaie, Khashayarsha , Dong, Haidong , Shapiro, Virginia Smith , Dong, Haidong , Shapiro, Virginia S , Friedman, David , Shapiro, Michael Jeremy , Liu, Xin

Mayo Clinic

Cancer Immunology Research | June 1, 2021 | Volume: 9 | Issue: 8 | Pages: 952-966

10.1158/2326-6066.cir-20-0834 | PMID 34074677 Get It

Abstract Many tumors exhibit increased incorporation of sialic acids into cell-surface glycans, which impact the tumor microenvironment. Sialic acid immunoglobulin-like lectins (Siglec) are receptors that recognize sialic acids and modulate immune responses, including responses to tumors. However, the roles of individual sialyltransferases in tumorigenesis and tumor growth are not well understood. Here, we examined the sialyltransferase ST8Sia6, which generated α2,8-linked disialic acids that bind to murine Siglec-E and human Siglec-7 and -9. Increased ST8Sia6 expression was found on many human tumors and associated with decreased survival in several cancers, including colon cancer. Because of this, we engineered MC38 and B16-F10 tumor lines to express ST8Sia6. ST8Sia6-expressing MC38 and B16-F10 tumors exhibited faster growth and led to decreased survival, which required host Siglec-E. ST8Sia6 expression on tumors also altered macrophage polarization toward M2, including upregulation of the immune modulator arginase, which also required Siglec-E. ST8Sia6 also accelerated tumorigenesis in a genetically engineered, spontaneous murine model of colon cancer, decreasing survival from approximately 6 months to 67 days. Thus, ST8Sia6 expression on tumors inhibits antitumor immune responses to accelerate tumor growth.
Surgical Resection After Talimogene Laherparepvec for Melanoma: Persistent Fuorodeoxyglucose Avidity on Positron Emission Tomography Despite No Viable Disease
Jakub, James W. , MacArthur, Taleen A. , Fahy, Aodhnait S. , Jakub, James W

Mayo Clinic

The American Surgeon™ | June 1, 2021 | Volume: 87 | Issue: 6 | Pages: 849-854

10.1177/00031348211023434 | PMID 34060947 Get It

Background Talimogene laherparepvec (TVEC) is an injectable attenuated oncolytic herpes simplex virus (HSV-1) used in the treatment of loco regionally metastatic melanoma. Lesions managed by TVEC are generally considered unresectable at time of initiation of intralesional therapy; however, a subset of patients go on to have surgical resection of loco regionally controlled disease. We sought to review our experience with surgical excision of treated lesions to offer an insight into the radiologic correlate, treatment effect, and pathological findings of intralesional TVEC therapy. Methods This is a retrospective descriptive case series of patients who underwent TVEC injection at Mayo Clinic, Rochester, MN, between October 2016 and July 2020. Institutional Institutional Review Board approval was obtained. Results Twenty-one patients underwent intralesional TVEC, met inclusion criteria, and were included in this series. Seven went on to surgical excision of the injected lesions after an initial course of TVEC. Of those 7 patients, 4 had residual melanoma in the specimen on final pathology, while 3 had a complete pathologic response. All 3 patients who had no residual disease on pathology continued to have fluorodeoxyglucose (FDG) avidity on preoperative positron emission tomography scan of the excised lesions. Discussion Despite ongoing FDG avidity on PET scan, patients who have well-controlled disease and stability over time of the injected lesions may benefit from surgical excision following a course of TVEC. This may render the patient clinically disease free and/or allow them a reprieve from TVEC treatment.
ATRT-07. DEFINING LOST AND GAINED TRANSCRIPTIONAL REGULATORY NETWORKS IN ATYPICAL TERATOID RHABDOID TUMOR
Wixom, Alex, Nesvick, Cody L. , Zhang, Liang N. , Wixom, Alexander Q. , Hamdan, Feda H. , Johnsen, Steven A. , Daniels, David J.

Mayo Clinic

Neuro-Oncology | June 1, 2021 | Volume: 23 | Issue: Supplement_1 | Pages: i2-i2

10.1093/neuonc/noab090.006 Get It

Abstract Atypical teratoid rhabdoid tumor (ATRT) is a central nervous system cancer of infancy and early childhood that may occur anywhere along the neuraxis and is associated with a high rate of mortality. While contemporary multimodal therapeutic approaches have significantly improved overall survival, targeted therapy remains elusive, and treatment is often associated with significant morbidity. ATRT is unique in its genomic stability, with the only recurrent genetic abnormality being bi-allelic loss of the SMARCB1 gene, which encodes a core subunit of the BAF chromatin remodeling complex. The epigenetic mechanisms by which SMARCB1 loss leads to tumorigenesis are not yet well-defined and addressing this gap in understanding is necessary for creating efficacious, targeted therapeutics. To better understand the epigenetic features gained and lost in ATRT, we re-expressed SMARCB1 in a library of patient-derived and established ATRT cell lines of multiple molecular subtypes. SMARCB1 restoration significantly reduced or eliminated the proliferative and clonogenic capacity of each cell line. We performed assay for transposase-accessible chromatin with high-throughput sequencing (ATAC-Seq) and RNA sequencing (RNA-Seq) to define putative transcriptional regulatory networks that are gained and lost in ATRT. SMARCB1 restoration was associated with global changes in chromatin openness consistent with the creation of new regulatory elements throughout the genome, and these were associated with induction of a diverse developmental transcriptional signature. Motif enrichment analysis of regions with increased accessibility defined a small but consistent number of centrally enriched transcription factor motifs across cell lines indicative of putative pioneer factors whose functions may be lost in ATRT. Pertinent chromatin immunoprecipitation with sequencing (ChIP-Seq) data will be discussed in the context of lost and gained transcriptional regulatory networks in ATRT and normal cellular development.
HGG-13. BRAIN DISTRIBUTION AND CLEARANCE OF ALISERTIB IS LIMITED BY PGP AND BCRP EFFLUX PUMPS AND DEPENDENT UPON DELIVERY METHOD
Oh, Ju‐Hee , Zhang, Liang , Elmquist, William F. , Power, Erica A. , Daniels, David J.

Mayo Clinic

Neuro-Oncology | June 1, 2021 | Volume: 23 | Issue: Supplement_1 | Pages: i20-i20

10.1093/neuonc/noab090.079 Get It

Abstract Diffuse midline gliomas (DMGs) harboring the H3K27M mutation are highly aggressive, uniformly fatal brain tumors that primarily occur in children. The blood-brain barrier (BBB), including drug efflux pumps, prevent numerous drugs from reaching CNS tumors at cytotoxic concentrations. Alisertib is an aurora kinase inhibitor that was previously identified in a drug screen as a compound of interest. However, its ability to penetrate the BBB is not well established. The goals of this study were two-fold: 1) determine the CNS distribution and clearance rates of alisertib following systemic delivery and if the BBB efflux pumps, Pgp and BCRP, alter distribution and clearance. 2) Compare alisertib distribution and clearance following convection-enhanced delivery to systemic results. WT and Pgp/BCRP knockout mice and Sprague-dawley rats underwent tail vein injection (mice and rats) or convection-enhanced delivery to the brainstem (rats only) of alisertib and sacrificed at 0, 2, 4, 8, 12, 16 and 24hours. The plasma and brain were collected and analyzed for alisertib concentration by HPLC-MS/MS. We found that in both mice and rats, alisertib concentration in the plasma and brain decreased biexponentially. Overall, Alisertib was found to be 3.14% brain penetrant. In Pgp/BCRP knockout mice, alisertib concentration in the plasma and brain decreased biexponentially, but was detected at higher concentration at all time points in the brain compared to WT mice. This resulted in a higher brain penetrance (17.26%). Differences based on anatomical brain region were significant in those rats which received convection-enhanced delivery. Alisertib was found in higher concentration in the pons and cerebellum compared to systemic delivery, but lower concentrations in the cortex and plasma. These results suggest that drug clearance may be a general mechanism limiting efficacy of drugs of interest and should be carefully considered during preclinical evaluation.
HGG-31. HISTONE H3.3 G34R/V MUTATIONS STIMULATE PEDIATRIC HIGH-GRADE GLIOMA FORMATION THROUGH THE INDUCTION OF CHROMOSOMAL INSTABILITY
Grigore, Florina , Langfald, Alyssa, Robinson, James, Hinchcliffe, Edward H. , Day, Charles

Mayo Clinic

Neuro-Oncology | June 1, 2021 | Volume: 23 | Issue: Supplement_1 | Pages: i23-i23

10.1093/neuonc/noab090.095 Get It

Abstract The histone H3.3 G34R/V mutations are known drivers of high-grade pediatric glioma (pHGG). However, the mechanism(s) for H3.3 G34R/V induced tumor formation are unclear. Chk1 phosphorylates H3.3 S31 at the pericentromere during early mitosis, suggesting a novel mitotic function. We observed that H3.3 G34 mutant pHGG cells have reduced mitotic H3.3 S31 phosphorylation compare to WT H3.3 cell lines. The H3.3 G34R mutation reduced Chk1 phosphorylation at S31 by >90% in an in vitro kinase assay. Overexpression of either H3.3 G34R or non-phosphorylatable S31A in H3.3 WT, diploid cells led to a significant increase in chromosome mis-segregations. Likewise, H3.3 G34 mutant pHGG cells have significantly elevated rates of mis-segregation as compare to H3.3 WT pHGG cells. During normal cell division, phospho-S31 is lost in late anaphase. However, when chromosome missegregation occurs, phospho-S31 spreads and stimulates p53 accumulation in G1 – thus suppressing aneuploid cell proliferation. Here we show that cells expressing mutant G34 fail to arrest following mis-segregation, despite having WT p53. These studies demonstrate that the H3.3 G34R/V mutations are sufficient to transform normal, diploid cells into proliferative, chromosomally instable cells. To determine if this process contributes to tumorigenesis, we used the RCAS/TVA mouse model to overexpress H3.3 WT, G34R, or S31A in the glial precursor cells of mice pups. Over 100 days, S31A and G34R mice had drastically reduced survival (averaging 77, 81, and 100 days for S31A, G34R, and WT mice). Furthermore, most G34R and S31A mice developed HGG, while H3.3 WT mice remained tumor-free and did not develop high-grade tumors. Our work strongly indicates that a major factor in H3.3 G34R pHGG formation is the induction of chromosomal instability – which occurs directly through the suppression of H3.3 S31 phosphorylation.
Phase II trial of proton therapy versus photon IMRT for GBM: secondary analysis comparison of progression-free survival between RANO versus clinical assessment
Feghali, Karine A. Al , Randall, James W. , Liu, Diane D. , Wefel, Jeffrey S. , Brown, Paul D. , Grosshans, David R. , McAvoy, Sarah , Farhat, Maguy , McGovern, Susan L. , McAleer, Mary Frances , Ghia, Amol J. , Peñas-Prado, Marta , Groot, John de, Heimberger, Amy B. , Mahajan, Anita , Guha‐Thakurta, Nandita , Chung, Caroline , Al Feghali, Karine A , Armstrong, Terri S , Wefel, Jeffrey S , Li, Jing , Paulino, Arnold C. , Sulman, Erik P. , Wang, Jihong , Heimberger, Amy B. , Armstrong, Terri S. , Gilbert, Mark R.

Mayo Clinic

Neuro-Oncology Advances | June 1, 2021 | Volume: 3 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdab073 | PMID 34337411 Get It

Abstract Background This secondary image analysis of a randomized trial of proton radiotherapy (PT) versus photon intensity-modulated radiotherapy (IMRT) compares tumor progression based on clinical radiological assessment versus Response Assessment in Neuro-Oncology (RANO). Methods Eligible patients were enrolled in the randomized trial and had MR imaging at baseline and follow-up beyond 12 weeks from completion of radiotherapy. “Clinical progression” was based on a clinical radiology report of progression and/or change in treatment for progression. Results Of 90 enrolled patients, 66 were evaluable. Median clinical progression-free survival (PFS) was 10.8 (range: 9.4–14.7) months; 10.8 months IMRT versus 11.2 months PT (P = .14). Median RANO-PFS was 8.2 (range: 6.9, 12): 8.9 months IMRT versus 6.6 months PT (P = .24). RANO-PFS was significantly shorter than clinical PFS overall (P = .001) and for both the IMRT (P = .01) and PT (P = .04) groups. There were 31 (46.3%) discrepant cases of which 17 had RANO progression more than a month prior to clinical progression, and 14 had progression by RANO but not clinical criteria. Conclusions Based on this secondary analysis of a trial of PT versus IMRT for glioblastoma, while no difference in PFS was noted relative to treatment technique, RANO criteria identified progression more often and earlier than clinical assessment. This highlights the disconnect between measures of tumor response in clinical trials versus clinical practice. With growing efforts to utilize real-world data and personalized treatment with timely adaptation, there is a growing need to improve the consistency of determining tumor progression within clinical trials and clinical practice.
Managing infliximab infusions after a drug holiday
Bhat, Shubha , Qazi, Taha , Farraye, Francis A.

Mayo Clinic

American Journal of Health-System Pharmacy | June 1, 2021 | Volume: 78 | Issue: 18 | Pages: 1664-1665

10.1093/ajhp/zxab234 | PMID 34059875 Get It

Efficacy of a Novel Penile Traction Device in Improving Penile Length and Erectile Function Post Prostatectomy: Results from a Single-Center Randomized, Controlled Trial
Toussi, Amir , Ziegelmann, Matthew , Yang, David Y. , Manka, Madeleine, Frank, Igor, Boorjian, Stephen A. , Tollefson, Matthew K. , Köhler, Tobias , Trost, Landon , Yang, David, Tollefson, Matthew, Yang Md, David

Mayo Clinic

Journal of Urology | June 1, 2021 | Volume: 206 | Issue: 2 | Pages: 416-426

10.1097/ju.0000000000001792 | PMID 34060339 Get It

Isolated tibial insert exchange in revision total knee arthroplasty
Tetreault, Matthew W. , Hines, Jeremy T. , Berry, Daniel J. , Pagnano, Mark W. , Trousdale, Robert T. , Abdel, Matthew P. , Abdel, Matthew P , Berry, Daniel J

Mayo Clinic

The Bone & Joint Journal | June 1, 2021 | Volume: 103-B | Issue: 6 | Pages: 1103-1110

10.1302/0301-620x.103b6.bjj-2020-1954.r2 | PMID 34058882 Get It

AimsThis study aimed to determine outcomes of isolated tibial insert exchange (ITIE) during revision total knee arthroplasty (TKA).MethodsFrom 1985 to 2016, 270 ITIEs were performed at one institution for instability (55%, n = 148), polyethylene wear (39%, n = 105), insert fracture/dissociation (5%, n = 14), or stiffness (1%, n = 3). Patients with component loosening, implant malposition, infection, and extensor mechanism problems were excluded.ResultsSurvivorship free of any re-revision was 68% at ten years. For the indication of insert wear, survivorship free of any re-revision at ten years was 74%. Re-revisions were more frequent for index diagnoses other than wear (hazard ratio (HR) 1.9; p = 0.013), with ten-year survivorships of 69% for instability and 37% for insert fracture/dissociation. Following ITIE for wear, the most common reason for re-revision was aseptic loosening (33%, n = 7). For other indications, the most common reason for re-revision was recurrence of the original diagnosis. Mean Knee Society Scores improved from 54 (0 to 94) preoperatively to 77 (38 to 94) at ten years.ConclusionAfter ITIE, the risk and reasons for re-revision correlated with preoperative indications. The best results were for polyethylene wear. For other diagnoses, the re-revision rate was higher and the failure mode was most commonly recurrence of the original indication for the revision TKA. Cite this article: Bone Joint J 2021;103-B(6):1103–1110.